Measuring depression severity based on facial expression and body movement using deep convolutional neural network

The application of artificial intelligence in insomnia, anxiety, and depression: A bibliometric analysis

Background

Mental health issues like insomnia, anxiety, and depression have increased significantly. Artificial intelligence (AI) has shown promise in diagnosing and providing personalized treatment.

Objective

This study aims to systematically review the application of AI in addressing insomnia, anxiety, and depression, identifying key research hotspots, and forecasting future trends through bibliometric analysis.

Methods

We analyzed a total of 875 articles from the Web of Science Core Collection (2000-2024) using bibliometric tools such as VOSviewer and CiteSpace. These tools were used to map research trends, highlight international collaboration, and examine the contributions of leading countries, institutions, and authors in the field.

Results

The United States and China lead the field in terms of research output and collaborations. Key research areas include "neural networks," "machine learning," "deep learning," and "human-robot interaction," particularly in relation to personalized treatment approaches. However, challenges around data privacy, ethical concerns, and the interpretability of AI models need to be addressed.

Conclusions

This study highlights the growing role of AI in mental health research and identifies future priorities, such as improving data quality, addressing ethical challenges, and integrating AI more seamlessly into clinical practice. These advancements will be crucial in addressing the global mental health crisis.

Pinocembrin alleviates LPS-induced depressive-like behavior in mice via the NLRP3/DCC signaling pathway

OBJECTIVE

Depression, a prevalent and severe mental disorder, continues to be a significant area of research concerning its pathogenesis and therapeutic approaches. Conventional antidepressants are often limited by delayed therapeutic effects and notable adverse reactions, necessitating the development of innovative and efficacious treatment modalities. Multiple lines of evidence suggest that peripheral and central inflammation play a role in depression, and that anti-inflammatory drugs can ameliorate depressive symptoms in patients with inflammation-related depression. Pinocembrin (PB), a natural bioactive compound, is renowned for its anti-inflammatory and antioxidant properties, while the effect and mechanism of PB are still unclear. Consequently, this study employs PB as an intervention to investigate its effects on depression in mice model, with the objective of establishing a novel therapeutic strategy and foundational data for the treatment of depression.

METHODS

(1) The acute inflammation model used lipopolysaccharide (LPS) to induce depression-like behavior in mice by injecting LPS intraperitoneally at a dose of 0.83 mg/kg. The effects of PB (20 mg/kg, i.p.) and the NLRP3 inflammasome inhibitor MCC950 (10 mg/kg, i.p.) on improving depression behavior in mice were evaluated. (2) To explore the specific mechanism of PB in improving depression-like behavior in LPS mice by regulating NLRP3 and Netrin-1/DCC pathway.

RESULTS

The results showed that after intraperitoneal injection of LPS, the mice exhibited a significant decrease in body weight, sucrose preference score, and a significant increase in tail suspension immobility time. Treatment with PB and MCC950 increased the sucrose preference score and decreased the tail suspension immobility time. Besides, PB and MCC950 could inhibit the expression of NLRP3 related neuroinflammation, down-regulated the Netrin-1/DCC signaling pathway, and improved hippocampal neuroplasticity in mice.

CONCLUSION

In conclusion, PB significantly improved LPS-induced depression-like behavior in mice by reducing the expression of hippocampal NLRP3 inflammasome and down-regulating the Netrin-1/DCC signaling pathway. Additionally, PB was found to regulate α-amino-3-hydroxy-5-methyl-4 isoxazole receptor (AMPAR) and postsynaptic density 95 (PSD95), protecting excitatory synaptic transmission and enhancing synaptic plasticity. This study demonstrates the effectiveness of PB in improving depressive symptoms induced by LPS and provides a new strategy for the clinical treatment of depression.

The Digitized Memory Clinic

Several major challenges, including an ageing population and declining workforce and the implementation of recent breakthrough therapies for Alzheimer disease, are prompting a necessary rethink of how people with neurodegenerative dementias are diagnosed and medically managed. Digital health technologies could play a pivotal part in this transformation, with new advances enabling the collection of millions of data points from a single individual. Possible applications include unobtrusive monitoring that aids early detection of disease and artificial intelligence-based health advice. To translate these advances to meaningful benefits for people living with a disease, technologies must be implemented within a system that retains the physician expert as a central figure in decision-making. This Perspective presents a new framework, termed the Digitized Memory Clinic, for the diagnostic pathway of neurodegenerative dementias that incorporates digital health technologies with currently available assessment tools, such as fluid and imaging biomarkers, in an interplay with the physician. The Digitized Memory Clinic will manage people across the entire disease spectrum, from the detection of risk factors for cognitive decline and the earliest symptoms to dementia, and will replace the present paradigm of a pure 'brick-and-mortar' memory clinic. Important ethical, legal and societal barriers associated with the implementation of digital health technologies in memory clinics need to be addressed. The envisioned Digitized Memory Clinic aims to improve diagnostics and enable precise disease-tracking prognostication for individuals with memory disorders and to open new possibilities, such as precision medicine for prevention and treatment.

Hepatic encephalopathy post-TIPS: Current status and prospects in predictive assessment

Transjugular intrahepatic portosystemic shunt (TIPS) is an essential procedure for the treatment of portal hypertension but can result in hepatic encephalopathy (HE), a serious complication that worsens patient outcomes. Investigating predictors of HE after TIPS is essential to improve prognosis. This review analyzes risk factors and compares predictive models, weighing traditional scores such as Child-Pugh, Model for End-Stage Liver Disease (MELD), and albumin-bilirubin (ALBI) against emerging artificial intelligence (AI) techniques. While traditional scores provide initial insights into HE risk, they have limitations in dealing with clinical complexity. Advances in machine learning (ML), particularly when integrated with imaging and clinical data, offer refined assessments. These innovations suggest the potential for AI to significantly improve the prediction of post-TIPS HE. The study provides clinicians with a comprehensive overview of current prediction methods, while advocating for the integration of AI to increase the accuracy of post-TIPS HE assessments. By harnessing the power of AI, clinicians can better manage the risks associated with TIPS and tailor interventions to individual patient needs. Future research should therefore prioritize the development of advanced AI frameworks that can assimilate diverse data streams to support clinical decision-making. The goal is not only to more accurately predict HE, but also to improve overall patient care and quality of life.

FM-FCN: A Neural Network with Filtering Modules for Accurate Vital Signs Extraction

Neural networks excel at capturing local spatial patterns through convolutional modules, but they may struggle to identify and effectively utilize the morphological and amplitude periodic nature of physiological signals. In this work, we propose a novel network named filtering module fully convolutional network (FM-FCN), which fuses traditional filtering techniques with neural networks to amplify physiological signals and suppress noise. First, instead of using a fully connected layer, we use an FCN to preserve the time-dimensional correlation information of physiological signals, enabling multiple cycles of signals in the network and providing a basis for signal processing. Second, we introduce the FM as a network module that adapts to eliminate unwanted interference, leveraging the structure of the filter. This approach builds a bridge between deep learning and signal processing methodologies. Finally, we evaluate the performance of FM-FCN using remote photoplethysmography. Experimental results demonstrate that FM-FCN outperforms the second-ranked method in terms of both blood volume pulse (BVP) signal and heart rate (HR) accuracy. It substantially improves the quality of BVP waveform reconstruction, with a decrease of 20.23% in mean absolute error (MAE) and an increase of 79.95% in signal-to-noise ratio (SNR). Regarding HR estimation accuracy, FM-FCN achieves a decrease of 35.85% in MAE, 29.65% in error standard deviation, and 32.88% decrease in 95% limits of agreement width, meeting clinical standards for HR accuracy requirements. The results highlight its potential in improving the accuracy and reliability of vital sign measurement through high-quality BVP signal extraction. The codes and datasets are available online at https://github.com/zhaoqi106/FM-FCN.

MoodCapture: Depression Detection Using In-the-Wild Smartphone Images

MoodCapture presents a novel approach that assesses depression based on images automatically captured from the front-facing camera of smartphones as people go about their daily lives. We collect over 125,000 photos in the wild from N=177 participants diagnosed with major depressive disorder for 90 days. Images are captured naturalistically while participants respond to the PHQ-8 depression survey question: "I have felt down, depressed, or hopeless". Our analysis explores important image attributes, such as angle, dominant colors, location, objects, and lighting. We show that a random forest trained with face landmarks can classify samples as depressed or non-depressed and predict raw PHQ-8 scores effectively. Our post-hoc analysis provides several insights through an ablation study, feature importance analysis, and bias assessment. Importantly, we evaluate user concerns about using MoodCapture to detect depression based on sharing photos, providing critical insights into privacy concerns that inform the future design of in-the-wild image-based mental health assessment tools.

Applied Artificial Intelligence in Healthcare: A Review of Computer Vision Technology Application in Hospital Settings

Computer vision (CV), a type of artificial intelligence (AI) that uses digital videos or a sequence of images to recognize content, has been used extensively across industries in recent years. However, in the healthcare industry, its applications are limited by factors like privacy, safety, and ethical concerns. Despite this, CV has the potential to improve patient monitoring, and system efficiencies, while reducing workload. In contrast to previous reviews, we focus on the end-user applications of CV. First, we briefly review and categorize CV applications in other industries (job enhancement, surveillance and monitoring, automation, and augmented reality). We then review the developments of CV in the hospital setting, outpatient, and community settings. The recent advances in monitoring delirium, pain and sedation, patient deterioration, mechanical ventilation, mobility, patient safety, surgical applications, quantification of workload in the hospital, and monitoring for patient events outside the hospital are highlighted. To identify opportunities for future applications, we also completed journey mapping at different system levels. Lastly, we discuss the privacy, safety, and ethical considerations associated with CV and outline processes in algorithm development and testing that limit CV expansion in healthcare. This comprehensive review highlights CV applications and ideas for its expanded use in healthcare.

Machine Learning for Multimodal Mental Health Detection: A Systematic Review of Passive Sensing Approaches

As mental health (MH) disorders become increasingly prevalent, their multifaceted symptoms and comorbidities with other conditions introduce complexity to diagnosis, posing a risk of underdiagnosis. While machine learning (ML) has been explored to mitigate these challenges, we hypothesized that multiple data modalities support more comprehensive detection and that non-intrusive collection approaches better capture natural behaviors. To understand the current trends, we systematically reviewed 184 studies to assess feature extraction, feature fusion, and ML methodologies applied to detect MH disorders from passively sensed multimodal data, including audio and video recordings, social media, smartphones, and wearable devices. Our findings revealed varying correlations of modality-specific features in individualized contexts, potentially influenced by demographics and personalities. We also observed the growing adoption of neural network architectures for model-level fusion and as ML algorithms, which have demonstrated promising efficacy in handling high-dimensional features while modeling within and cross-modality relationships. This work provides future researchers with a clear taxonomy of methodological approaches to multimodal detection of MH disorders to inspire future methodological advancements. The comprehensive analysis also guides and supports future researchers in making informed decisions to select an optimal data source that aligns with specific use cases based on the MH disorder of interest.

Telepsychiatry in the Treatment of Major Depressive Disorders

This chapter explores the transformative role of telepsychiatry in managing major depressive disorders (MDD). Traversing geographical barriers and reducing stigma, this innovative branch of telemedicine leverages digital platforms to deliver effective psychiatric care. We investigate the evolution of telepsychiatry, examining its diverse interventions such as videoconferencing-based psychotherapy, medication management, and mobile applications. While offering significant advantages like increased accessibility, cost-effectiveness, and improved patient engagement, challenges in telepsychiatry include technological barriers, privacy concerns, ethical and legal considerations, and digital literacy gaps. Looking forward, emerging technologies like virtual reality, artificial intelligence, and precision medicine hold immense potential to personalize and enhance treatment effectiveness. Recognizing its limitations and advocating for equitable access, this chapter underscores telepsychiatry's power to revolutionize MDD treatment, making quality mental healthcare a reality for all.

A Dynamic Probabilistic Model for Heterogeneous Data Fusion: A Pilot Case Study from Computer-Aided Detection of Depression

The present paper, in the framework of a search for a computer-aided method to detect depression, deals with experimental data of various types, with their correlation, and with the way relevant information about depression delivered by different sets of data can be fused to build a unique body of knowledge about individuals' mental states facilitating the diagnosis and its accuracy. To this aim, it suggests the use of a recently introduced «limiting form» of the kinetic-theoretic language, at present widely used to describe complex systems of objects of the most diverse nature. In this connection, the paper mainly aims to show how a wide range of experimental procedures can be described as examples of this «limiting case» and possibly rendered by this description more effective as methods of prediction from experience. In particular, the paper contains a simple, preliminary application of the method to the detection of depression, to show how the consideration of statistical parameters connected with the analysis of speech can modify, at least in a stochastic sense, each diagnosis of depression delivered by the Beck Depression Inventory (BDI-II).